Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503

Objective: EAPB0503, lead compound of imiqualines, presented high antitumor activities but also a very low water solubility which was critical for further preclinical studies. To apply to EAPB0503, a robust and safe lipid formulation already used for poor soluble anticancer agents for injectable administration at a concentration higher than 1 mg/mL. Materials and Methods: Physicochemical properties of EAPB0503 were determined to consider an adapted formulation. In a second time, lipid nanocapsules (LNC) formulations based on the phase-inversion process were developed for EAPB0503 encapsulation. Then, EAPB0503 loaded-LNC were tested in vitro on different cell lines and compared to standard EAPB0503 solutions. Results: Optimized EAPB0503 LNC displayed an average size of 111.7 ± 0.9 nm and a low polydispersity index of 0.059 ± 0.002. The obtained loading efficiency was higher than 96% with a drug loading of 1.7 mg/mL. A stability study showed stability during 4 weeks stored at 25°C. In vitro results highlighted similar efficiencies between LNC and standard EAPB0503 solutions prepared in dimethyl sulfoxide. Conclusion: In view of results obtained for loading efficiency and drug loading, the use of a LNC formulation is very interesting to permit the solubilization of a lipophilic drug and to improve its bioavailability. Preliminary tested pharmaceutical formulation applied to EAPB0503 significantly improved its water solubility and will be soon considered for future preclinical in vivo studies.

[1]  N. Bec,et al.  New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationships. , 2016, Bioorganic & medicinal chemistry.

[2]  G. Storm,et al.  Liposomal doxorubicin: the good, the bad and the not-so-ugly , 2016, Journal of drug targeting.

[3]  Qiang Zhang,et al.  Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo. , 2015, International journal of pharmaceutics.

[4]  L. Bezdetnaya,et al.  Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics , 2015, Drugs.

[5]  M. Cordeiro,et al.  Quinoxaline, its derivatives and applications: A State of the Art review. , 2015, European journal of medicinal chemistry.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[8]  J. Benoit,et al.  In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor. , 2015, Nanomedicine.

[9]  V. Mamedov,et al.  Advances in the synthesis of imidazo[1,5-]- and imidazo[1,2-]quinoxalines , 2014 .

[10]  R. Nasr,et al.  EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells , 2014, Anti-cancer drugs.

[11]  J. Benoit,et al.  Polyglutamic acid-PEG nanocapsules as long circulating carriers for the delivery of docetaxel. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  F. Bressolle,et al.  Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry. , 2014, Journal of pharmaceutical and biomedical analysis.

[13]  J. Benoit,et al.  Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Soodabeh Davaran,et al.  Liposome: classification, preparation, and applications , 2013, Nanoscale Research Letters.

[15]  M. Gallarate,et al.  Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery , 2012, Expert opinion on drug delivery.

[16]  J. Benoit,et al.  The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. , 2010, Nanomedicine.

[17]  F. Pinguet,et al.  Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas , 2010, Drug Metabolism and Disposition.

[18]  A. Lamprecht,et al.  In vitro drug release mechanism from lipid nanocapsules (LNC). , 2010, International journal of pharmaceutics.

[19]  F. Pinguet,et al.  New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma. , 2009, European journal of medicinal chemistry.

[20]  F. Pinguet,et al.  Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS. , 2009, Journal of separation science.

[21]  M. Baccarani,et al.  Liposomal daunorubicin versus standard daunorubicin: long term follow‐up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia , 2008, British journal of haematology.

[22]  F. Pinguet,et al.  In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. , 2008, Bioorganic & medicinal chemistry.

[23]  Y. Kfoury,et al.  EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. , 2008, Blood.

[24]  J. Benoit,et al.  Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. , 2007, Biomaterials.

[25]  J. Benoit,et al.  A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats , 2006, Molecular Cancer Therapeutics.

[26]  J. Benoit,et al.  Electrokinetic properties of noncharged lipid nanocapsules: Influence of the dipolar distribution at the interface , 2005, Electrophoresis.

[27]  R. Strickley Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[28]  J. Benoit,et al.  A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers , 2002, Pharmaceutical Research.

[29]  베아뜨리스 에르따울,et al.  Lipid nanocapsules, preparation method and use as medicine , 2001 .

[30]  D. Wood,et al.  Continued studies in the toxicology of dimethyl sulfoxide (DMSO). , 1971, The Journal of pharmacology and experimental therapeutics.

[31]  M. De Allegri,et al.  How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  J. Benoit,et al.  The influence of lipid nanocapsule composition on their size distribution. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.